Jithin Mathew | Cancer Biology | Best Researcher Award

Best Researcher Award

Jithin Mathew – Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences

Jithin Mathew

Affiliation Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences
Country India
Google Scholar ID MPJU3OgAAAAJ&hl
Documents 21
Citations 49
h-index 2
Subject Area Cancer Biology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-1545-4342
Scopus ID 59313773600

Jithin Mathew is a pharmaceutical researcher and academic affiliated with Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences, India. His scholarly work encompasses cancer biology, pharmacological investigations and pharmaceutical sciences. His publications address therapeutic approaches, drug formulation and the investigation of bioactive compounds. His research profile demonstrates contributions across multiple areas of pharmaceutical and biomedical research.[1]

Abstract

Jithin Mathew’s research profile reflects academic contributions to pharmaceutical sciences, with particular interest in cancer biology and pharmacological research. His published studies include investigations into radiopharmaceutical approaches to cancer treatment, herbal-derived phytochemicals and pharmaceutical formulation development. His scholarly record, comprising 21 documents and 49 citations, provides a basis for evaluating his research activity and academic contributions.[1]

Keywords

Jithin Mathew, Cancer Biology, Pharmaceutical Sciences, Pharmacology, Radiopharmaceuticals, Herbal Phytochemicals, Drug Formulation, Cancer Research, Pharmaceutical Research.

Introduction

Pharmaceutical research plays an important role in exploring therapeutic strategies, improving drug delivery and understanding disease-related mechanisms. Jithin Mathew’s academic publications address these research areas through review articles and investigations involving pharmacological applications, natural compounds and pharmaceutical formulations. His work contributes to scholarly discussions in pharmaceutical and biomedical sciences.[3]

Research Profile

According to his Google Scholar profile, Jithin Mathew has 21 listed documents, 49 citations and an h-index of 2. His academic affiliation is with the Department of Pharmacology at NGSM Institute of Pharmaceutical Sciences. His documented research interests include cancer biology and rheumatology, reflecting an interdisciplinary background in pharmaceutical and biomedical research.[1]

Research Contributions

His research contributions include work on radiopharmaceuticals in cancer therapy, herbal-derived phytochemicals in hepatocellular carcinoma and the development of fast-dissolving pharmaceutical formulations. These publications explore different aspects of therapeutic research, including molecular targets, formulation techniques and potential applications in disease management.[3][5]

Publications

Among his listed publications, Revolutionizing Cancer Treatment: The Role of Radiopharmaceuticals in Modern Cancer Therapy (2024) examines targeted radiopharmaceutical approaches. Another publication investigates the development of Propranolol HCl fast-dissolving tablets using isolated Salvia hispanica mucilage. His 2026 review on herbal-derived phytochemicals discusses molecular targets and tumour microenvironment interventions in hepatocellular carcinoma.[3][4][5]

Research Impact

His Google Scholar profile records 49 citations and an h-index of 2. The radiopharmaceutical cancer therapy review is listed with 43 citations, indicating notable citation activity among the publications displayed in the supplied profile. These indicators provide measurable information about the visibility and academic reach of his published research.[1][3]

Award Suitability

Jithin Mathew’s publication record, research activity and contributions to pharmaceutical sciences provide relevant academic credentials for consideration for the Best Researcher Award. His work across cancer biology, pharmacological research and pharmaceutical formulation demonstrates engagement with different areas of scientific investigation. His profile is presented for consideration under the International Top Pharmaceutical Awards.[1][2]

Conclusion

Jithin Mathew’s academic profile highlights research contributions in pharmaceutical sciences, cancer biology and pharmacology. His publications and citation record demonstrate ongoing scholarly activity across therapeutic and formulation-related research. His work provides a documented foundation for recognition and evaluation within the pharmaceutical research community.

External Links

References

  1. Google Scholar. (2026). Jithin Mathew – Author Profile and Publication Records. https://scholar.google.com/citations?user=MPJU3OgAAAAJ&hl=en
  2. International Top Pharmaceutical Awards. (n.d.). Official Awards Website. https://toppharmaceutical.org/
  3. Varghese, T. P., John, A., & Mathew, J. (2024). Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy. Precision Radiation Oncology, 8(3), 145–152. https://onlinelibrary.wiley.com/doi/10.1002/pro6.1239
  4. Mathew, J., et al. (2024). Design and development of Propranolol HCl fast dissolving tablets by using isolated mucilage of Salvia Hispanica for the treatment of hypertension by using DoE tools. Chinese Journal of Applied Physiology, 40, e20240025. DOI: 10.62958/j.cjap.2024.025. Publication record
  5. Mathew, J., Erattil Ahammed, S. Y., Salah, G. B., Elghazaly, A., Farhana, S. A., & Hussain, S. M. (2026). Herbal-derived phytochemicals in hepatocellular carcinoma: A review of molecular targets and tumor microenvironment interventions. Journal of Herbmed Pharmacology, 15(1), 11–26. DOI: 10.34172/jhp.2026.53276.

“`

Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award

Dr. Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award

Al-Quds University | Palestine

Dr. Mohammad Awlad Mohammad is a medical doctor and emerging researcher affiliated with the Faculty of Medicine at Al-Quds University, specializing in clinical medicine and translational research. He completed his medical degree with a strong academic record, complemented by advanced training in scientific writing, systematic reviews, and research ethics. His clinical experience includes surgical electives and pathology observerships, where he developed practical competencies in operative assistance, diagnostic workflows, and patient-centered care. Actively engaged in research, his work focuses on clinical case studies, oncology disparities, neurological therapeutics, and evidence-based analysis, contributing as both first and co-author to peer-reviewed publications, including studies on acute appendicitis atypical presentation and thoracic oncology disparities, alongside ongoing projects in multiple sclerosis and GLP-1 receptor agonists. He has demonstrated leadership through participation in research camps and academic collaborations, strengthening interdisciplinary inquiry. His certifications in Basic and Advanced Cardiac Life Support and research training programs reflect a commitment to clinical excellence and scientific integrity, positioning him as a promising contributor to advancing medical research and practice.

View ORCID Profile

 


Top Featured Publications

 

Dr. Elisabeth Daguenet|Cancer research|Best Researcher Award

Dr. Elisabeth Daguenet | Cancer research|Best Researcher Award

Dr. Elisabeth Daguenet at CHU de Saint-Etienne,France

PROFILE  

scopus

 

Early Academic Pursuits 🎓

The journey into chronic myeloid leukemia (CML) research for many esteemed researchers began with a strong foundation in biomedical sciences, often pursued at prominent universities worldwide. Individuals drawn to this field typically engage in intensive studies in molecular biology, genetics, and oncology. By acquiring a strong academic base, they develop a passion for understanding cancer biology and molecular pathways, which ultimately leads to a specialization in CML, a type of blood cancer that has evolved significantly in terms of treatment and patient prognosis.

Early on, these researchers often excel in various scientific competitions, securing scholarships or internships, which provide invaluable laboratory experience. Many join research teams focusing on leukemia, gaining insights into molecular dynamics, cellular responses, and how early molecular response (EMR) can predict deeper responses in CML patients.

Professional Endeavors in Chronic Myeloid Leukemia 🧬

As they advance in their careers, these scientists and oncologists become affiliated with medical institutions, research hospitals, and pharmaceutical companies dedicated to advancing leukemia treatment. Their work emphasizes real-world data collection, the accuracy of clinical trials, and translating laboratory findings into practical treatment solutions for CML patients.

In professional settings, they may lead trials to evaluate tyrosine kinase inhibitors (TKIs)—a cornerstone treatment for CML—and examine patients’ responses to these drugs. These trials often reveal trends, such as the role of the initial molecular response in predicting a deep molecular response, which can influence treatment protocols. However, these studies also underscore that EMR alone may not guarantee treatment-free remission (TFR) maintenance, particularly in real-world settings. Through these roles, they often mentor young scientists and clinicians, fostering a new generation of leukemia researchers.

Contributions and Research Focus 🧫

The contributions of researchers in this field are substantial, especially in the exploration of CML treatment responses. Their research often focuses on identifying biomarkers that predict EMR, deep molecular response (DMR), and the viability of treatment-free remission (TFR). This research is crucial as it helps clinicians understand which patients are more likely to maintain remission after stopping treatment, potentially enhancing their quality of life by reducing dependency on medications.

Their work also explores the impact of various TKIs on the molecular response, aiming to discover why some patients maintain remission without treatment while others do not. The analysis of “real-world” cohorts—patients outside of clinical trial settings—adds a vital dimension to this research, providing a more practical perspective on how different factors impact TFR. Additionally, these studies often examine the psychological and social aspects of remission in leukemia patients, ensuring a holistic approach to cancer care.

Accolades and Recognition 🏅

Researchers who make strides in understanding CML are often recognized by prestigious oncology and hematology organizations worldwide. They may receive awards such as “Young Investigator Awards” or “Lifetime Achievement” distinctions from organizations like the European Hematology Association (EHA), American Society of Hematology (ASH), or similar bodies. These awards celebrate their commitment to advancing leukemia treatment and improving patient outcomes.

Publications in high-impact journals, invitations to speak at global conferences, and editorial roles in scientific publications also bring recognition. Through these platforms, they share their findings with a wider audience, spreading knowledge that shapes the future of CML treatment.

Impact and Influence 🌟

The impact of this work extends far beyond individual patient outcomes, transforming the landscape of CML treatment globally. Researchers studying the initial molecular response in CML patients play a significant role in refining the approach to personalized medicine. By highlighting the nuances of TFR maintenance, they guide oncologists in creating treatment plans tailored to each patient’s molecular profile, fostering a more effective and patient-centered treatment protocol.

Furthermore, this research influences medical guidelines, ensuring that healthcare providers have the most current information on EMR and DMR in real-world settings. This influence translates into better decision-making for oncologists worldwide, who can offer more accurate prognoses and support to CML patients.

Legacy and Future Contributions 🌱

The legacy of these researchers is one of resilience, innovation, and dedication to improving lives. Their work has fundamentally shifted the understanding of CML and has inspired a focus on achieving TFR, a dream outcome for many cancer patients. By shedding light on the predictors of TFR and the limitations of relying solely on EMR for treatment decisions, they encourage ongoing research that pushes the boundaries of cancer treatment.

In the future, the work may inspire genetic and pharmacological advancements, enabling scientists to uncover new biomarkers or develop novel TKIs with fewer side effects. Their research also lays a foundation for upcoming generations of cancer researchers, fostering a continuous cycle of inquiry, discovery, and refinement in leukemia treatment.

Conclusion 📝

In summary, the pursuit of understanding the molecular response in CML patients represents an extraordinary commitment to scientific advancement and patient care. These researchers build a legacy that impacts lives on a personal and global scale, contributing to the evolution of oncology and the prospect of a world where CML remission and ultimately cure become a widespread reality. Through their efforts, CML patients around the world can hope for not only better treatments but a pathway toward sustained remission and a life free from cancer treatment.

🎓Publication 

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

  • Authors   :Saugues, S., Lambert, C., Daguenet, E., … Pereira, B., Berger, M.G.
  • Journal    : Haematologica
  • Year         :2024

Baseline DSB repair prediction of chronic rare Grade ≥ 3 toxicities induced by radiotherapy using classification algorithms

  • Authors   : Muggiolu, G., Sauvaigo, S., Libert, S., … Deutsch, E., Magné, N.
  • Journal    : Radiation Research
  • Year         :2024

Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study

  • Authors   :Garderet, L., Ouldjeriouat, H., Bekadja, M.-A., … Lambert, J., Cornillon, J.
  • Journal    : British Journal of Haematology
  • Year         :2024

Differential Formation of Stress Granules in Radiosensitive and Radioresistant Head and Neck Squamous Cell Carcinoma Cells

  • Authors   : Louati, S., Wozny, A.-S., Malesys, C., … Magné, N., Rodriguez-Lafrasse, C.
  • Journal    :International Journal of Radiation Oncology Biology Physics
  • Year         :2024

Correction to: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party (Bone Marrow Transplantation

  • Authors   :Penack, O., Peczynski, C., Boreland, W., … Moiseev, I., Peric, Z.
  • Journal    :Bone Marrow Transplantation
  • Year         :2024